Paper · 36980339
Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study.
Jhuo YC and 12 others. Diagnostics (Basel), 2023. Cited by 8 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study. Papers, record 36980339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980339
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17,634,536 | Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17634536 | PubMed |
| 2 | 30,367,205 | The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. | World J Urol | 2019 | https://conductscience.org/library/papers/30367205 | PubMed |
| 3 | 19,399,023 | Cancer micrometastases. | Nat Rev Clin Oncol | 2009 | https://conductscience.org/library/papers/19399023 | PubMed |
| 4 | 35,020,204 | Cancer statistics, 2022. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35020204 | PubMed |
| 5 | 22,277,196 | Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. | Eur Urol | 2012 | https://conductscience.org/library/papers/22277196 | PubMed |
| 6 | 30,728,860 | Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. | Ther Adv Urol | 2019 | https://conductscience.org/library/papers/30728860 | PubMed |
| 7 | 34,356,529 | Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma. | Biology (Basel) | 2021 | https://conductscience.org/library/papers/34356529 | PubMed |
| 8 | 17,326,057 | Detection of circulating urothelial cancer cells in the blood using the CellSearch System. | Cancer | 2007 | https://conductscience.org/library/papers/17326057 | PubMed |
| 9 | 22,908,097 | Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22908097 | PubMed |
| 10 | 22,580,852 | Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. | Ann Surg | 2012 | https://conductscience.org/library/papers/22580852 | PubMed |
1 to 10 of 47
See all 47 referencesCited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,676,582 | Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/40676582 | PubMed |
| 40,234,713 | Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation. | Nat Rev Urol | 2025 | https://conductscience.org/library/papers/40234713 | PubMed |
| 40,027,303 | A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells. | J Liq Biopsy | 2024 | https://conductscience.org/library/papers/40027303 | PubMed |
| 39,567,681 | Metastasis development in non-muscle-invasive bladder cancer. | Nat Rev Urol | 2025 | https://conductscience.org/library/papers/39567681 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CMPK1 | 51,727 | PubTator's text mining | https://conductscience.org/library/genes/51727 | NCBI Gene |
| EPCAM | 4,072 | PubTator's text mining | https://conductscience.org/library/genes/4072 | NCBI Gene |
| NPEPPS | 9,520 | PubTator's text mining | https://conductscience.org/library/genes/9520 | NCBI Gene |
| PDCD1 | 5,133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| PTPRC | 5,788 | PubTator's text mining | https://conductscience.org/library/genes/5788 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36980339
GET https://conductscience.org/api/papers/v1/36980339/references?page=2